Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Immunoglobulin Light-chain Amyloidosis

ClinicalTrials.gov lists 235 trials for Immunoglobulin Light-chain Amyloidosis or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 7.

MeSH D000075363 Neoplasms Neoplasm C04 C18 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 45 Phase 1/2 Phase 1/2 23 Phase 2 Phase 2 69 Phase 3 Phase 3 28 Phase 4 Phase 4 1 Not applicable Not applicable 23 Observational Observational 44 Expanded access Expanded access 1 Phase 1 Phase 1 45 Phase 1/2 Phase 1/2 23 Phase 2 Phase 2 69 Phase 3 Phase 3 28 Phase 4 Phase 4 1 Not applicable Not applicable 23 Observational Observational 44 Expanded access Expanded access 1

Trials per phase (log scale)

1 more section with rows

235 of the 235 trials are tagged with Immunoglobulin Light-chain Amyloidosis itself; the rest are tagged with a narrower condition beneath it.

Get the Immunoglobulin Light-chain Amyloidosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Immunoglobulin Light-chain Amyloidosis trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Expanded access
  • Other (Unknown)

Top of scale: 18

1991: 1 trials (Phase 2 1) 1992: 1 trials (Phase 2 1) 1996: 2 trials (Phase 2 2) 1997: 5 trials (Phase 2 1, Phase 1/2 1, Phase 1 3) 1998: 5 trials (Phase 3 1, Phase 2 1, Phase 1 3) 1999: 13 trials (Not applicable 1, Phase 3 3, Phase 2 4, Phase 1 5) 2000: 10 trials (Observational 1, Not applicable 1, Phase 3 4, Phase 2 2, Phase 1/2 2) 2001: 4 trials (Phase 2 2, Phase 1 2) 2002: 4 trials (Not applicable 1, Phase 2 1, Phase 1 2) 2003: 2 trials (Observational 1, Phase 3 1) 2004: 4 trials (Observational 1, Phase 2 2, Phase 1 1) 2005: 7 trials (Observational 2, Phase 3 2, Phase 2 2, Phase 1/2 1) 2006: 4 trials (Not applicable 2, Phase 3 1, Phase 2 1) 2007: 10 trials (Expanded access 1, Observational 1, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 1) 2008: 12 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 3, Phase 1/2 2, Phase 1 3) 2009: 12 trials (Other 1, Observational 5, Not applicable 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2010: 6 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 2) 2011: 5 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 1 2) 2012: 5 trials (Not applicable 1, Phase 2 3, Phase 1/2 1) 2013: 5 trials (Phase 2 2, Phase 1/2 1, Phase 1 2) 2014: 2 trials (Phase 2 1, Phase 1 1) 2015: 5 trials (Observational 2, Phase 3 2, Phase 2 1) 2016: 6 trials (Observational 1, Not applicable 1, Phase 2 2, Phase 1 2) 2017: 7 trials (Phase 2 3, Phase 1/2 3, Phase 1 1) 2018: 7 trials (Observational 1, Not applicable 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2019: 4 trials (Observational 4) 2020: 10 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 1, Phase 1 1) 2021: 10 trials (Observational 1, Phase 2 5, Phase 1/2 1, Phase 1 3) 2022: 8 trials (Observational 3, Phase 2 2, Phase 1/2 1, Phase 1 2) 2023: 10 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 2, Phase 1 3) 2024: 16 trials (Observational 5, Not applicable 2, Phase 3 1, Phase 2 2, Phase 1/2 4, Phase 1 2) 2025: 18 trials (Observational 5, Not applicable 4, Phase 2 6, Phase 1/2 1, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 14
2025 18
2024 16
2023 10
2022 8
2021 10
2020 10
2019 4
2018 7
2017 7

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 16 trials starting in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 30 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 146 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Immunoglobulin Light-chain Amyloidosis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 45
Phase 1/2 23
Phase 2 69
Phase 3 28
Phase 4 1
Not applicable 23
Observational 44
Expanded access 1
Unknown 1

How many Immunoglobulin Light-chain Amyloidosis trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 7
Recruiting 45
Enrolling by invitation 3
Active, not recruiting 13
Completed 121

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Immunoglobulin Light-chain Amyloidosis trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 7
Prothena Biosciences Ltd. 6
SWOG Cancer Research Network 6
Alexion Pharmaceuticals, Inc. 5
GlaxoSmithKline 5

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Immunoglobulin Light-chain Amyloidosis? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Melphalan 27
Cytoxan 23
POMALIDOMIDE 8
IXAZOMIB 6

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 44
Bortezomib SC 20
Filgrastime (G-CSF) 18
Peripheral blood stem cell transplantation 16
Daratumumab SC 11

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Immunoglobulin Light-chain Amyloidosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 88 11
Cardiac Failure 63 3
Regimen Related Toxicity 63 1
Cardiac failure 52 5
Syncope 52 11

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Immunoglobulin Light-chain Amyloidosis? (63)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Early experience with daratumumab-containing regimens in patients with light-chain cardiac amyloidosis. Journal of cardiology 2025 Yes
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes
Molecular Stratification of Light-Chain Cardiac Amyloidosis With <sup>18</sup>F-Florbetapir and <sup>68</sup>Ga-FAPI-04 for Enhanced Prognostic Precision. JACC. Cardiovascular imaging 2025 Yes
Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis. Blood 2025 Yes
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702). Blood 2025 Yes

Showing 5 of 63 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (162)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
AL amyloidosis Point prevalence 1-9 / 100 000 United Kingdom GB Exact
AL amyloidosis Point prevalence 1-9 / 100 000 United Kingdom GB Exact
AL amyloidosis Annual incidence 1-9 / 100 000 United Kingdom GB Exact
AL amyloidosis Annual incidence 1-9 / 100 000 United Kingdom GB Exact
AL amyloidosis Annual incidence 1-9 / 1 000 000 United States US Exact

Showing 5 of 162 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
AL amyloidosis 85443 Exact Orphadata Science knowledge files, Product 1
AL amyloidosis 85443 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages